$102.61
0.30% yesterday
Nasdaq, Oct 14, 10:00 pm CET
ISIN
US09075V1026
Symbol
BNTX

BioNTech SE - ADR Stock price

$102.61
+4.73 4.83% 1M
+0.27 0.26% 6M
-11.34 9.95% YTD
-17.53 14.59% 1Y
-33.01 24.34% 3Y
+16.90 19.71% 5Y
+88.56 630.22% 10Y
+88.56 630.22% 20Y
Nasdaq, Closing price Tue, Oct 14 2025
+0.31 0.30%
ISIN
US09075V1026
Symbol
BNTX
Industry

Key metrics

Basic
Market capitalization
$24.6b
Enterprise Value
$8.6b
Net debt
positive
Cash
$16.3b
Shares outstanding
240.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.4 | 9.8
EV/Sales
2.6 | 3.4
EV/FCF
negative
P/B
1.1
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$3.3b | $2.5b
EBITDA
$-454.3m | $-1.7b
EBIT
$-807.0m | $-1.9b
Net Income
$-400.9m | $-1.4b
Free Cash Flow
$-3.0b
Growth (TTM | estimate)
Revenue
7.0% | -21.1%
EBITDA
25.4% | -65.3%
EBIT
5.2% | -40.0%
Net Income
31.5% | -78.7%
Free Cash Flow
-208.7%
Margin (TTM | estimate)
Gross
84.2%
EBITDA
-13.6% | -65.6%
EBIT
-24.2%
Net
-12.0% | -54.8%
Free Cash Flow
-88.9%
Financial Health
Equity Ratio
86.2%
Return on Equity
-3.4%
ROCE
-3.5%
ROIC
-10.6%
Debt/Equity
0.0
More
EPS
$-1.7
FCF per Share
$-12.4
Short interest
6.7%
Employees
7k
Rev per Employee
$470.0k
Show more

Is BioNTech SE - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

BioNTech SE - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a BioNTech SE - ADR forecast:

22x Buy
76%
7x Hold
24%

Analyst Opinions

29 Analysts have issued a BioNTech SE - ADR forecast:

Buy
76%
Hold
24%

Financial data from BioNTech SE - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,342 3,342
7% 7%
100%
- Direct Costs 530 530
15% 15%
16%
2,812 2,812
6% 6%
84%
- Selling and Administrative Expenses 628 628
10% 10%
19%
- Research and Development Expense - -
-
-
-454 -454
25% 25%
-14%
- Depreciation and Amortization 353 353
46% 46%
11%
EBIT (Operating Income) EBIT -807 -807
5% 5%
-24%
Net Profit -401 -401
32% 32%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about BioNTech SE - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioNTech SE - ADR Stock News

Neutral
The Motley Fool
7 days ago
On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of certain drugs in the U.S. and investing in local manufacturing efforts. This deal lifted not only Pfizer, but also much of the healthcare sector, especially the company's drugmaking peers, as Wall...
Neutral
Seeking Alpha
14 days ago
BioNTech SE, InstaDeep Ltd - Special Call Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Karim Beguir Alexandre Laterre Bernardo Almeida Bora Guloglu Nicolas Lopez Carranza Youssef Ben Dhieb Cheng Zhang Antoine Delaunay Conference Call Participants Lexi Walls Michael Rooney Michael Pye - Baillie Gifford Overseas Limited Presentation Unknown Executive Hi. Good ...
Positive
The Motley Fool
14 days ago
Germany-based BioNTech (BNTX 3.64%) saw its U.S. listed stock enjoy a mini-pop on Wednesday, and for once this wasn't largely based on the Comirnaty COVID-19 vaccine it developed with Pfizer. Rather, investors seemed to be cheered by the biotech's continuing efforts to harness artificial intelligence (AI) technology.
More BioNTech SE - ADR News

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.

Head office Germany
CEO Ugur Sahin
Employees 6,772
Founded 2008
Website www.biontech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today